Home › Funds › Empery Asset Management, LP › XFOR
Empery Asset Management, LP position in XFOR
X4 PHARMACEUTICALS INC · Health Care
Empery Asset Management, LP reported holding 6,930,591 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$32.4M, representing 37.43% of its reported portfolio and ranking #1 among its reported holdings. Empery Asset Management, LP has disclosed XFOR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Empery Asset Management, LP's XFOR position evolved
Empery Asset Management, LP first disclosed a stake in XFOR in Q4 2025 at 8,951,105 shares (US$35.8M). The position peaked in Q1 2026 at 8,944,118 shares, worth US$36.9M. Across 3 filings, Empery Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,930,591 shares valued at US$32.4M — a reduction of -2,013,527 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 8.95M | $35.80M | New |
| Q1 2026 | 8.94M | $36.94M | Hold |
| Q2 2026 | 6.93M | $32.37M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in XFOR — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$37.2M), PERCEPTIVE ADVISORS LLC (US$37.0M), Saturn V Capital Management LP (US$32.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $37.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 7.93M sh · $37.05M · Q2 2026
- Saturn V Capital Management LP 6.97M sh · $32.57M · Q2 2026
- Deep Track Capital, LP 5.88M sh · $27.45M · Q2 2026
- Kalehua Capital Management LLC 3.72M sh · $17.39M · Q2 2026
- NEA Management Company, LLC 3.23M sh · $15.10M · Q2 2026
- Rosalind Advisors, Inc. 3.21M sh · $15.01M · Q2 2026
- Trails Edge Capital Partners, LP 2.57M sh · $12.01M · Q2 2026
- BVF INC/IL 2.23M sh · $10.43M · Q2 2026
- Venrock Adviser, LLC 1.93M sh · $9.03M · Q2 2026
- Samsara BioCapital, LLC 1.40M sh · $6.52M · Q2 2026
- Verdad Advisers, LP 352.09K sh · $1.64M · Q2 2026
More on Empery Asset Management, LP
FAQ
How long has Empery Asset Management, LP held XFOR?
Empery Asset Management, LP has disclosed XFOR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Empery Asset Management, LP's current position in XFOR?
As of Q2 2026, Empery Asset Management, LP holds 6.93M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $32.37M, representing 37.43% of its reported portfolio and ranking #1.
Has Empery Asset Management, LP been buying or selling XFOR?
In the latest 13F filing (Q2 2026), Empery Asset Management, LP reduced its position in XFOR. The position peaked in Q1 2026 at 8.94M shares.
Which other funds hold XFOR?
Other major institutional holders of XFOR include Bain Capital Life Sciences Investors, LLC, PERCEPTIVE ADVISORS LLC, Saturn V Capital Management LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.